Fig 1: rDKK3 inhibited the activation of ASK1/JNK/p-38 signaling pathway in rats with neuropathic pain. a rDKK3 could increase the reduced protein expression level of DKK3 in neuropathic pain rats (**p < 0.01 compared with Sham + Vehicle group, ###p < 0.001 compared with SNI + Vehicle group, n = 6 in each group). b, c Western blot results indicated that the protein level of ASK1 in sham and SNI rats treated with Vehicle or rDKK3 had no significant change, while rDKK3 down-regulated the elevated protein expression level of p-ASK1 induced by neuropathic pain in the spinal cord (**p < 0.01 compared with Sham + Vehicle group, ###p < 0.001 compared with SNI + Vehicle group, n = 6 in each group). d, e Western blot results indicated that the protein level of JNK in sham and SNI rats applied with Vehicle or rDKK3 had no significant change, while rDKK3 down-regulated the increased protein expression level of p-JNK caused by neuropathic pain in the spinal cord (****p < 0.0001 compared with Sham + Vehicle group, ####p < 0.0001 compared with SNI + Vehicle group, n = 6 in each group). f, g Western blot result indicated that the protein level of p38 in sham and SNI rats administrated with Vehicle or rDKK3 had no significant change, while rDKK3 alleviated the increased protein expression level of p-p38 in the spinal cord of rats with neuropathic pain (****p < 0.0001 compared with Sham + Vehicle group, ####p < 0.0001 compared with SNI + Vehicle group, n = 6 in each group)
Fig 2: miR-124-1 inhibits tumorigenesis via the p38-Akt-JNK pathwayA, B. The activity of the JNK pathway was evaluated in MHCC-LM3 (A) and Huh7 (B) cells transfected with si-CASC3. The activity of the JNK pathway in HCC cells infected with a control lentiviral vector or an miR-124-1expression lentiviral vector was assessed after transduction with a lentiviral vector encoding CASC3 (open reading frame without the 3'-UTR).
Fig 3: Model showing the role of iRhom2 as a positive regulator of PM2.5-induced renal injury. iRhom2 played an essential role in regulating the progression of renal injury in PM2.5-exposed mice, most likely through activating TACE/TNFRs and I?Ba/NF-?B signaling pathways to promote inflammation. In addition, iRhom2 inactivated HO-1/Nrf-2 pathway, whereas activated JNK expression to enhance oxidative stress, thus exacerbating renal injury.
Fig 4: Effects of a recombinant secreted protein acidic and rich in cysteine (rSPARC) and an integrin aVß3 inhibitor at 24 h after modeling. (a) rSPARC exacerbates modified Garcia's score and inhibition of integrin aVß3 suppresses the effects of rSPARC after SAH (n = 6 per group). *P < 0.05 and **P < 0.01. (b) Representative Western blot images and densitometric quantification of expression of phosphorylated p46 and p54 c-Jun N-terminal kinase (p-JNK), phosphorylated p38 (p-p38), interleukin (IL)-6, pro and active matrix metalloproteinase (MMP)-9, ZO-1, and vascular endothelial- (VE-) cadherin. Representative Western blots come from the same samples but multiple membranes. Expression levels of each protein are assessed using ß-actin as an internal control: the levels are expressed as the target protein/ß-actin, p-p38/p38, or p-JNK/JNK and as a ratio of the average level of the sham + PBS group for normalization, because the levels of p38 and JNK are unchanged among the groups (mean ± standard deviation; n = 6 per group). *P < 0.05 and **P < 0.01 vs. sham + phosphate-buffered saline (PBS), †P < 0.05 and ‡P < 0.01 vs. Sham + rSPARC, §P < 0.05 and ¶P < 0.01 vs. SAH + PBS, #P < 0.05 and ##P < 0.01 vs. SAH + rSPARC. cRGD: cyclo(-RGDfK): integrin aVß3 inhibitor.
Fig 5: Models showing that iRhom2 is a positive regulator of alcohol-induced liver fibrosis; iRhom2 plays an important role in regulating the progression of liver fibrosis in alcohol-exposed mice, most likely by activating the TACE/TNFRs/NF-?B signaling pathway to promote inflammation. In addition, iRhom2 exacerbates liver fibrotic lesions by activating JNK expression to enhance oxidative stress via the Nrf2/HO-1 pathway.
Supplier Page from Abcam for Anti-JNK1+JNK2 (phospho T183 + Y185) antibody